The study, published in the journal Medical Oncology, was led by Saumyadeep Bora and Hitesh Kulhari of the School of Nano Sciences at the Central University of Gujarat, with collaborators from JSS Academy of Higher Education and Research, Parul University, and additional investigators at the Central University of Gujarat. The team set out to solve a problem that has shadowed cordycepin since its earliest characterization: the molecule, formally known as 3′-deoxyadenosine, is structurally almost identical to adenosine, the nucleoside that cells use constantly for energy transfer and signaling. That similarity makes cordycepin a prime target for adenosine deaminase, an abundant enzyme that chemically deaminates the compound and strips it of its anticancer activity within a short time of entering circulation.

The pharmacokinetic obstacles do not stop there. In the stomach, cordycepin encounters a strongly acidic environment that destabilizes the molecule before it can even be absorbed. Once absorbed, its poor pharmacokinetic profile means that little of an administered dose survives long enough or concentrates sufficiently in tumor tissue to do meaningful damage. Conventional cancer therapies suffer from a related cluster of problems, including low bioavailability, non-selective targeting of healthy tissues, and toxicity at the high doses often needed to achieve an effect. Rather than modifying cordycepin itself, the researchers chose to shield it, using a delivery technology that has matured steadily over the past two decades: solid lipid nanoparticles, or SLNs.

Solid lipid nanoparticles are spherical carriers typically tens to a few hundred nanometers across, built from lipids that remain solid at body temperature. A hydrophobic or amphiphilic drug can be dissolved in the molten lipid matrix during preparation, and as the lipid solidifies, the drug becomes entrapped within the particle core. Compared with polymeric nanoparticles, SLNs offer several practical advantages: they can be produced without organic solvents, they use biocompatible excipients, they protect labile molecules from enzymatic and chemical degradation, and they can sustain drug release over extended periods. Their lipid composition also encourages uptake by cell membranes, which are themselves lipid-rich, a property the researchers hoped to exploit to increase how much cordycepin actually gets inside cancer cells.

The team formulated cordycepin-loaded SLNs, abbreviated CSLN, and subjected them to a battery of characterization tests. The resulting particles were monodispersed, meaning they fell within a narrow, uniform size range, a critical property for reproducible drug delivery because particle size governs both circulation behavior and cellular uptake. Imaging and physical characterization confirmed that the particles were spherical and possessed good physical and chemical stability, indicating that the encapsulated drug would not prematurely leak or degrade during storage or transport. Uniform, stable, well-formed particles are the baseline requirement for any nanoformulation to move credibly toward preclinical evaluation, and the CSLN system appears to meet that baseline.

Release behavior was examined under two pH conditions designed to mimic different biological compartments. In acidic conditions, which correspond to the endo-lysosomal environment that nanoparticles encounter after being swallowed by cells, and at physiological pH, which corresponds to the pH of systemic circulation, the CSLN formulations exhibited sustained release of their cargo. This pH-responsive, prolonged release profile serves a dual purpose. In the bloodstream, slow release limits the burst exposure that drives off-target toxicity and rapid clearance. Inside the tumor cell’s acidic vesicles, release is retained, ensuring that the drug is liberated precisely where it can most effectively reach its intracellular targets rather than being lost in the extracellular environment.

The functional payoff of this engineering showed up clearly in cytotoxicity assays against MCF-7 cells, a widely used human breast cancer cell line. Compared with free cordycepin administered in its conventional soluble form, the CSLN formulation significantly enhanced the compound’s cytotoxic effect. The researchers attribute this improvement to two linked mechanisms. First, improved cellular uptake: nanoparticles are internalized by cells through endocytic pathways that free small molecules cannot use, allowing far greater quantities of the drug to accumulate inside the cell. Second, the sustained intracellular release keeps drug levels high at the relevant sites for longer, rather than allowing the compound to be quickly exported or degraded. Together, these effects convert a drug that struggles to reach its target into one that arrives in force and lingers.

Higher intracellular accumulation translated into greater apoptotic activity, meaning the treated cancer cells were more likely to undergo programmed cell death, the controlled self-destruction pathway that cordycepin is known to activate in tumor cells. The study also reported more pronounced clonogenic activity effects, indicating a measurable impact on the ability of surviving cells to proliferate and form colonies. Prior work has established that cordycepin can induce apoptosis in breast cancer cells through caspase-dependent pathways, and can act independently of the estrogen receptor, which matters because MCF-7 cells are estrogen receptor positive and many breast cancers lose endocrine responsiveness over time. The nanoformulation amplifies this intrinsic apoptotic potential simply by getting more intact drug to the right place.

The new work builds on, and differentiates itself from, a growing body of research into cordycepin delivery systems. Previous studies have encapsulated cordycepin in poly(lactic-co-glycolic acid) nanoparticles with improved cytotoxicity and reduced hemotoxicity, loaded it into bovine serum albumin nanoparticles, complexed it with cyclodextrins to improve stability, and formulated CD44-targeted lipid polymer hybrid nanoparticles carrying Cordyceps militaris extracts. Liposome-encapsulated nanocordycepin has also shown enhanced activity in breast and cervical cancer cells. The present study’s contribution is to demonstrate that solid lipid nanoparticles, a simpler and arguably more clinically friendly platform given their biocompatible composition and solvent-free preparation, achieve the same essential goals: protection from adenosine deaminase, resistance to acidic degradation, sustained pH-responsive release, and greater intracellular delivery.

For now, the findings rest on in vitro evidence, and the usual caveats apply: nanoparticle behavior in cell culture does not always predict performance in living animals, where protein adsorption, immune clearance, and tumor heterogeneity complicate the picture. The authors note that their data are available upon reasonable request, and the work was supported by institutional resources at the Central University of Gujarat, JSS Academy of Higher Education and Research, and Parul University, with doctoral fellowships from the University Grants Commission. Even so, the study adds a meaningful data point to one of nanomedicine’s most persistent arguments, that the fastest route to new cancer drugs sometimes runs not through novel molecules but through smarter packaging of old ones. For a compound isolated from a parasitic fungus that has been used in Chinese and Tibetan medicine for centuries, a lipid shell a few hundred nanometers wide may be exactly what it takes to finally make the leap from promising natural product to working therapy.

Subject of Research: Solid lipid nanoparticle delivery of cordycepin for breast cancer therapy

Article Title: Overcoming cordycepin limitations with SLNs-based nanoformulation: formulation development and cytotoxicity evaluation against human breast cancer cells

Article References: Overcoming cordycepin limitations with SLNs-based nanoformulation: formulation development and cytotoxicity evaluation against human breast cancer cells. (n.d.). https://doi.org/10.1007/s12032-026-03407-2

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03407-2

Keywords: cordycepin, solid lipid nanoparticles, breast cancer, MCF-7 cells, nanomedicine, drug delivery, apoptosis, adenosine deaminase, cytotoxicity, natural products, chemotherapy, nanoencapsulation

The research began in the field. Specimens were collected from Gool in District Ramban, at altitudes of roughly 2,500 to 3,500 meters above sea level, during the monsoon months between June and August. The club-shaped, orange stromata the researchers found were closely associated with insect larvae and pupae, whose bodies the fungus had colonized and mummified with its mycelium. Back at the Plant Pathology, Mycology and Microbiology Laboratory in Srinagar, the team documented the fungus’s macroscopic anatomy in detail, noting stromata measuring 3.8 to 6.2 centimeters in length, semi-immersed ovoid perithecia, and the darker fertile heads that signal maturity.

Identification did not rest on appearance alone. Microscopic examination revealed subcylindrical conidiophores, slender flask-shaped phialides, and variably shaped conidia, along with eight-spored cylindrical asci containing filiform ascospores. The researchers then turned to molecular tools, extracting DNA by the CTAB method and amplifying the internal transcribed spacer region of the ribosomal DNA with the universal primers ITS-1F and ITS-4R. Sequencing showed 99.78 percent identity with a reference strain of C. militaris, and the sequence was deposited in GenBank under accession number PQ810010. A maximum-likelihood phylogenetic analysis of 18 ITS sequences placed the Kashmir isolate firmly within the C. militaris species complex, supported by a bootstrap value of 100 percent. The specimen itself was preserved as voucher number 9337-KASH in the herbarium at the University of Kashmir.

With identity confirmed, the researchers set out to solve a practical problem: the fungus grows slowly. On ordinary Sabouraud’s dextrose agar, C. militaris needed roughly 27 to 28 days to cover a plate, and the full cultivation cycle to mature stromata in prior work stretched to two or three months. For a fungus whose value lies in compounds such as cordycepin, adenosine, gamma-aminobutyric acid, ergothioneine, lovastatin, carotenoids and a suite of minerals, time is money. The team compared four solid media, Sabouraud’s dextrose agar, potato dextrose agar, corn meal agar and Richard’s synthetic agar, measuring mycelial diameter every three days over three weeks of incubation at 25 degrees Celsius.

Sabouraud’s dextrose agar emerged as the clear winner, producing the maximum mycelial growth of 54.0 millimeters after 21 days, ahead of potato dextrose agar, corn meal agar and Richard’s synthetic agar. But the researchers did not stop there. Knowing that the carbon-to-nitrogen ratio strongly influences mycelial growth in this species, they supplemented the best medium with malt extract, a rich carbon source, and yeast extract, a rich nitrogen source. Malt extract at 6 grams per liter pushed the colony diameter to 70.30 millimeters, but adding more than that brought no further gain. The decisive step came with yeast extract: the optimal combination of 6 grams per liter malt extract and 4 grams per liter yeast extract produced the maximum diameter of 84.60 millimeters after just 17 days of incubation, roughly ten days faster than unsupplemented Sabouraud’s medium.

Faster mycelium is only half the battle; producing the fruiting bodies, or stromata, that contain the medically interesting compounds requires moving the fungus onto solid substrates. Here the team prepared liquid inoculum in two nutrient broths of differing sugar and nitrogen composition, agitating flasks on a shaker at 170 revolutions per minute for up to eight days. Broth I, based on dextrose with peptone and yeast extract plus magnesium sulfate, potassium phosphate and vitamin B1, produced visible growth after seven days, five days sooner than broth II. The liquid mycelial culture also colonized grain substrates faster than mycelium grown on solid media, confirming that liquid spawn is the more efficient route to fruiting.

For the cultivation trials, the researchers chose four locally available and inexpensive grains: brown rice, white rice, corn kernels and wheat. Each 20-gram portion of grain received 45 milliliters of one of the two nutritional broths before sterilization and inoculation. Jars were incubated in darkness at 20 degrees Celsius and 65 to 70 percent relative humidity for the spawn run, then exposed to fluorescent light at 800 to 1,000 lux for twelve hours daily at 85 to 90 percent humidity to trigger primordia formation and stroma development. The logic of using local grains was deliberate: they are cheap, produced by regional farmers, and sustainable, reducing production costs for would-be growers in Jammu and Kashmir.

The results were unambiguous. Brown rice combined with nutritional broth I delivered the fastest performance on every measure: a spawn run of only 14 days, primordia after 11.5 days, and mature stromata after about 25.75 days, for a total cultivation cycle of 51.25 days from inoculation to harvest, the shortest of any combination tested. This substrate pairing also produced the longest stromata, at 78.0 millimeters on average, and the greatest number of stromata per jar, roughly 63 compared with a low of about 28 on wheat grain with broth II. Most strikingly, brown rice with broth I achieved a biological efficiency, the ratio of fresh yield to dry substrate weight, of 72.75 percent, far outperforming corn, white rice and wheat. Wheat grains did produce the thickest stromata, at just over 4 millimeters in diameter, but nowhere near the overall yield of brown rice.

The findings align with a growing international literature. Previous studies have found brown rice superior for C. militaris fruiting, reported maximum stroma yields on whole rice grains at slightly acidic pH, and shown that grain type and vitamin supplementation significantly shape mycelial growth and antioxidant capacity. Other work has optimized liquid culture conditions, identifying ideal glucose, yeast extract and mineral concentrations for biomass production. What distinguishes the Kashmir study is its focus on a wild, locally isolated strain rather than a commercial or imported one. Local strains may carry physiological adaptations to regional climate and substrates, and the authors argue that strain-specific optimization of this kind offers new insight into how cultivation protocols should be tailored to geographic origin rather than assumed universal.

The practical implications reach beyond mycology. C. militaris was approved by China’s Ministry of Public Health in 2009 as the first novel food of its kind, and its bioactive profile is considered comparable to that of the rare and costly caterpillar fungus Ophiocordyceps sinensis, making it a viable substitute in both traditional and modern therapeutic applications. Cordycepin and adenosine, its flagship compounds, show antibacterial, antioxidant, anti-inflammatory and anticancer activities in laboratory studies. By shortening the cultivation cycle, specifying cheap local substrates, and demonstrating conditions, 20 degrees Celsius, moderate humidity and a simple light regimen, that small facilities can maintain, the Kashmir team has laid a foundation for sustainable commercial cultivation that could benefit mushroom growers and entrepreneurs across the Indian Himalayas while easing pressure on wild populations.

Subject of Research: Optimization of nutrient media and grain substrates for the commercial cultivation of the wild medicinal fungus Cordyceps militaris from Jammu and Kashmir.

Article Title: Nutrient media and substrate optimization for commercial cultivation of Cordyceps militaris (L.) Fr., a novel medicinal mushroom from Jammu and Kashmir

Article References: Shrikhandia, P., Lone, S. A., Wani, A. H., & Bhat, M. Y. (2026). Nutrient media and substrate optimization for commercial cultivation of Cordyceps militaris (L.) Fr., a novel medicinal mushroom from Jammu and Kashmir. Discover Biotechnology, 3(1), Article 3. https://doi.org/10.1007/s44340-026-00048-z

Image Credits: AI Generated

DOI: 10.1007/s44340-026-00048-z

Keywords: Cordyceps militaris, medicinal mushroom, cultivation, substrate optimization, brown rice, cordycepin, mycelial growth, biological efficiency, Jammu and Kashmir, entomopathogenic fungus, Sabouraud dextrose agar, stroma formation